1. Calne R.Y., White D.J., Thiru S., Evans D.B., McMaster P., Dunn D.C., Craddock G.N., Pentlow B.D., Rolles K.. Cyclosporin A in patients receiving renal allografts from cadaver donors.
Lancet 2:1978;1323–1327.
2. Spencer C.M., Goa K.L., Gillis J.C.. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.
Drugs 54:1997;925–975.
3. Palestine A.G., Austin HA 3rd, Balow J.E., Antonovych T.T., Sabnis S.G., Preuss H.G., Nussenblatt R.B.. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?
Am J Transplant 4:2004;1289–1295.
4. Mayer A.D., Dmitrewski J., Squifflet J.P., Besse T., Grabensee B., Klein B., Eigler F.W., Heemann U., Pichlmayr R., Behrend M., Vanrenterghem Y., Donck J., van Hooff J., Christiaans M., Morales J.M., Andres A., Johnson R.W.G., Short C., Buchholz B., Rehmert N., Land W., Schleibner S., Forsythe J.L.R., Talbot D., Neumayer H.H., Hause I., Ericzon B.G., Brattstrom C., Claesson K., Muhlbacher F., Pohanka E.. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group.
Transplantation 64:1997;436–443.
5. Palestine A.G., Austin H.A. 3rd, Balow J.E., Antonovych T.T., Sabnis S.G., Preuss H.G., Nussenblatt R.B.. Renal histopathologic alterations in patients treated with cyclosporine for uveitis.
N Engl J Med 314:1986;1293–1298.
6. Ekberg H., Tedesco-Silva H., Demirbas A., Vítko S., Nashan B., Gürkan A., Margreiter R., Hugo C., Grinyó J.M., Frei U., Vanrenterghem Y., Daloze P., Halloran P.F.. Reduced exposure to calcineurin inhibitors in renal transplantation.
N Engl J Med 357:2007;2562–2575.
7. Oberbauer R.. Improved renal function in de novo renal transplant patients on sirolimus maintenance therapy following discontinuation of cyclosporine.
Ther Drug Monit 27:2005;7–9.
8. Fahr A.. Cyclosporin clinical pharmacokinetics.
Clin Pharmacokinet 24:1993;472–495.
9. Habedank D., Kung T., Karhausen T., von Haehling S., Doehner W., Schefold J.C., Hasper D., Reinke S., Anker S.D., Reinke P.. Exercise capacity and body composition in living-donor renal transplant recipients over time.
Nephrol Dial Transplant 24:2009;3854–3860.
10. Dmitrewski J., Krentz A.J., Mayer A.D., Buckels J.A., Barnes A.D., Smith J., Nattrass M.. Metabolic and hormonal effects of tacrolimus (FK506) or cyclosporin immunosuppression following renal transplantation.
Diabetes Obes Metab 3:2001;287–292.
11. Boland J., Atkinson K., Britton K., Darveniza P., Johnson S., Biggs J.. Tissue distribution and toxicity of cyclosporin A in the mouse.
Pathology 16:1984;117–123.
12. Pisitkun T., Eiam-Ong S., Chusil S., Praditpornsilpa K., Pansin P., Tungsanga K.. The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients.
Transplant Proc 34:2002;3173–3175.
13. Uchida K., Tominaga Y., Haba T., Katayama T., Matsuoka S., Sato T., Goto N., Takeda A., Morozumi K., Takagi H.. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation.
Transplant Proc 34:2002;1736–1737.
14. Wong K.M., Shek C.C., Chau K.F., Li C.S.. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients.
Am J Kidney Dis 35:2000;660–666.
15. Plosker G.L., Foster R.H.. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.
Drugs 59:2000;323–389.
16. Henry M.L.. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles.
Clin Transplant 13:1999;209–220.
17. Iwasaki K.. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.
Drug Metab Pharmacokinet 22:2007;328–335.
18. Rodrigo E., de Cos M.A., Sánchez B., Ruiz J.C., Piñera C., Fernández-Fresnedo G., Palomar R., Pérez-Ceballos M.A., Cotorruelo J.G., Zubimendi J.A., de Francisco A.L., Arias M.. High initial blood levels of tacrolimus in overweight renal transplant recipients.
Transplant Proc 37:2005;1453–1454.
19. Flechner S.M., Kolbeinsson M.E., Tam J., Lum B.. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients.
Transplantation 47:1989;806–810.
20. Kasap B., Soylu A., Turkmen M., Kavukcu S., Bora S., Gulay H.. Effect of obesity and overweight on cyclosporine blood levels and renal functions in renal adolescent recipients.
Transplant Proc 38:2006;463–465.
21. Orofino L., Pascual J., Quereda C., Burgos J., Marcen R., Ortuno J.. Influence of overweight on survival of kidney transplant.
Nephrol Dial Transplant 12:1997;855.
22. Hortal L., Fernandez A., Losada A., Lorenzo M., Baamonde E., Plaza C., Gallego R., Vega N., Palop L.. Study of the cyclosporine concentration at 2 hours in stable renal transplant patients and relation to body mass index.
Transplant Proc 33:2001;3110–3111.
23. Mafra D., Guebre-Egziabher F., Fouque D.. Body mass index, muscle and fat in chronic kidney disease: questions about survival.
Nephrol Dial Transplant 23:2008;2461–2466.
24. Han S.S., Heo N.J., Na K.Y., Chae D.W., Kim Y.S., Kim S., Chin H.J.. Age- and gender-dependent correlations between body composition and chronic kidney disease.
Am J Nephrol 31:2010;83–89.
25. Han S.S., Kim K.W., Kim K.I., Na K.Y., Chae D.W., Kim S., Chin H.J.. Lean mass index: a better predictor of mortality than body mass index in elderly Asians.
J Am Geriatr Soc 58:2010;312–317.
26. Keogh J.B., Tsalamandris C., Sewell R.B., Jones R.M., Angus P.W., Nyulasi I.B., Seeman E.. Bone loss at the proximal femur and reduced lean mass following liver transplantation: a longitudinal study.
Nutrition 15:1999;661–664.
27. Nawaratne S., Brien J.E., Seeman E., Fabiny R., Zalcberg J., Cosolo W., Angus P., Morgan D.J.. Relationships among liver and kidney volumes, lean body mass and drug clearance.
Br J Clin Pharmacol 46:1998;447–452.
28. Morgan D.J., Bray K.M.. Lean body mass as a predictor of drug dosage. Implications for drug therapy.
Clin Pharmacokinet 26:1994;292–307.
29. De Baerdemaeker L.E., Mortier E.P., Struys M.M.. Pharmacokinetics in obese patients.
Continuing Education in Anaesthesia, Critical Care & Pain 4:2004;152–155.
30. Hesselink D., van Schaik R., van der Heiden I., van der Werf M., Gregoor P., Lindemans J., Weimar W., van Gelder T.. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Clinical Pharmacology & Therapeutics 74:2003;245–254.